Addiction treatment in Maryland

The 578 licensed addiction-treatment facilities in Maryland operate within a regulatory framework defined by state law, federal parity requirements (MHPAEA, as strengthened by the 2024 final rule), and the clinical criteria each facility elects to adopt. This document evaluates that landscape systematically.

The Medicaid question

Regarding Medicaid: Maryland expanded Medicaid in 2014 under the Affordable Care Act. Has realistic access to Medicaid coverage for addiction treatment once enrolled. The policy distinction is particularly salient because it determines whether the state's uninsured low-income adult population has a reliable pathway into the treatment system or must navigate non-Medicaid options (county funds, sliding scale, charity care).

The overdose-mortality context

Drug-overdose mortality in Maryland: 49.6 deaths per 100,000 residents (CDC final 2023 data). This places the state within a specific cluster of the national distribution and carries implications for treatment prioritization — particularly around fentanyl test-strip distribution, naloxone availability, and MAT induction capacity at emergency-department and community-treatment points of entry. The specific context: Baltimore fentanyl mortality versus suburban treatment-capacity gap.

How access actually works in Maryland

The 578 licensed facilities in Maryland include a mix of hospital-system, private-equity-owned, nonprofit, and state-funded programs. Outcome research consistently finds more variation within categories than across them, which means the clinical-framework question (ASAM-aligned? MAT-offered? evidence-based programming?) is a more productive filter than the ownership-structure question. The specific context: Baltimore fentanyl mortality versus suburban treatment-capacity gap.

What to do next

Three institutional documents should be obtained before facility admission in Maryland: (1) a current Summary of Benefits and Coverage from the insurer; (2) the plan's behavioral-health medical-necessity criteria (disclosable under 2024 parity rule); (3) a verification-of-benefits letter from the proposed facility's utilization-review team. Admission without these three risks a post-admission cost-sharing dispute that is administratively expensive to resolve.